Literature DB >> 20233972

High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease.

Florencia Palacios1, Pilar Moreno, Pablo Morande, Cecilia Abreu, Agustín Correa, Valentina Porro, Ana Ines Landoni, Raul Gabus, Mirta Giordano, Guillermo Dighiero, Otto Pritsch, Pablo Oppezzo.   

Abstract

Interaction of chronic lymphocytic leukemia (CLL) B cells with tissue microenvironment has been suggested to favor disease progression by promoting malignant B-cell growth. Previous work has shown expression in peripheral blood (PB) of CLL B cells of activation-induced cytidine deaminase (AID) among CLL patients with an unmutated (UM) profile of immunoglobulin genes and with ongoing class switch recombination (CSR) process. Because AID expression results from interaction with activated tissue microenvironment, we speculated whether the small subset with ongoing CSR is responsible for high levels of AID expression and could be derived from this particular microenvironment. In this work, we quantified AID expression and ongoing CSR in PB of 50 CLL patients and characterized the expression of different molecules related to microenvironment interaction. Our results show that among UM patients (1) high AID expression is restricted to the subpopulation of tumoral cells ongoing CSR; (2) this small subset expresses high levels of proliferation, antiapoptotic and progression markers (Ki-67, c-myc, Bcl-2, CD49d, and CCL3/4 chemokines). Overall, this work outlines the importance of a cellular subset in PB of UM CLL patients with a poor clinical outcome, high AID levels, and ongoing CSR, whose presence might be a hallmark of a recent contact with the microenvironment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233972     DOI: 10.1182/blood-2009-12-257758

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.

Authors:  Montserrat Cols; Carolina M Barra; Bing He; Irene Puga; Weifeng Xu; April Chiu; Wayne Tam; Daniel M Knowles; Stacey R Dillon; John P Leonard; Richard R Furman; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

2.  Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells.

Authors:  María Belén Almejún; Mercedes Borge; Ana Colado; Esteban Enrique Elías; Enrique Podaza; Denise Risnik; Carlos Daniel De Brasi; Carmen Stanganelli; Irma Slavutsky; María Cabrejo; Horacio Fernández-Grecco; Raimundo Fernando Bezares; Santiago Cranco; Rubén Ángel Burgos; Julio César Sánchez-Ávalos; Pablo Oppezzo; Mirta Giordano; Romina Gamberale
Journal:  Haematologica       Date:  2017-03-30       Impact factor: 9.941

3.  Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation.

Authors:  F Palacios; C Abreu; D Prieto; P Morande; S Ruiz; T Fernández-Calero; H Naya; G Libisch; C Robello; A I Landoni; R Gabus; G Dighiero; P Oppezzo
Journal:  Leukemia       Date:  2014-05-14       Impact factor: 11.528

Review 4.  CD38 and chronic lymphocytic leukemia: a decade later.

Authors:  Fabio Malavasi; Silvia Deaglio; Rajendra Damle; Giovanna Cutrona; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

Review 5.  Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

Authors:  Jan A Burger
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

6.  Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.

Authors:  Piers E M Patten; Gerardo Ferrer; Shih-Shih Chen; Rita Simone; Sonia Marsilio; Xiao-Jie Yan; Zachary Gitto; Chaohui Yuan; Jonathan E Kolitz; Jacqueline Barrientos; Steven L Allen; Kanti R Rai; Thomas MacCarthy; Charles C Chu; Nicholas Chiorazzi
Journal:  JCI Insight       Date:  2016-04-07

7.  Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy.

Authors:  Kiyoko Kawamura; Akihiko Wada; Ji-Yang Wang; Quanhai Li; Akihiro Ishii; Hideki Tsujimura; Toshiyuki Takagi; Makiko Itami; Yuji Tada; Koichiro Tatsumi; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-16       Impact factor: 4.553

8.  HSP90 inhibitors decrease AID levels and activity in mice and in human cells.

Authors:  Damien Montamat-Sicotte; Ludivine C Litzler; Cecilia Abreu; Shiva Safavi; Astrid Zahn; Alexandre Orthwein; Markus Müschen; Pablo Oppezzo; Denise P Muñoz; Javier M Di Noia
Journal:  Eur J Immunol       Date:  2015-05-18       Impact factor: 5.532

9.  Regulation of activation-induced deaminase stability and antibody gene diversification by Hsp90.

Authors:  Alexandre Orthwein; Anne-Marie Patenaude; El Bachir Affar; Alain Lamarre; Jason C Young; Javier M Di Noia
Journal:  J Exp Med       Date:  2010-11-01       Impact factor: 14.307

10.  IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.

Authors:  Piers E M Patten; Charles C Chu; Emilia Albesiano; Rajendra N Damle; Xiao-Jie Yan; Dorothy Kim; Lu Zhang; Amanda R Magli; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Sergio Roa; Patricia K Mongini; Thomas MacCarthy; Matthew D Scharff; Nicholas Chiorazzi
Journal:  Blood       Date:  2012-10-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.